Innovation Pharmaceuticals (OTCMKTS: IPIX) has announced that it has met complete patient registration for its double-blind, randomized placebo-controlled second phase clinical study of Brilacidin in treating hospitalized patients with moderate to severe COVID-19. The company is developing the drug for COVID-19 treatment under the FDA Fast Track Designation.
Innovation Pharmaceuticals enrolled 120 patients in the Brilacidin study
A total of 120 dosed participants were recruited across several sites for the research. Final data gathering for the last patient enrolled in the study will be in early August, which will be study day 60. The process of unblinding research data will follow before the company releases topline study results.
CEO Leo Ehrlich said, “We are pleased to have reached this company milestone and particularly thank all of the participating investigator sites and patients, in addition to many others involved in supporting the completion of study enrollment, especially given the challenges brought on by the pandemic. Encouraged by extensive laboratory-based Brilacidin antiviral research focused on coronaviruses, and building on previous pre-clinical and clinical results demonstrating a robust Brilacidin therapeutic profile, we prioritized the development of Brilacidin as a novel antiviral. To us, this is much more than a COVID-19 study.”
Brilacidin had demonstrated potency in various viruses
The company’s goal is to develop a wide range of antivirals for not only the COVID-19 pandemic but also for other infectious diseases and deadly viruses that might arise. Ehrlich said that they are looking forward to the Brilacidin COVID-19 study readout.
Brilacidin, according to pre-clinical tests, has the potential to directly damage the viral structure, a powerful virucidal capability that allows it to be unaffected by mutations that cause variants—a useful trait that distinguishes Brilacidin from the other antivirals. Brilacidin has also shown effective and consistent suppression of coronaviruses, bunyaviruses, and alphaviruses, in vitro, indicating that it has potential as a broad-spectrum antiviral.